Dr. Niloofar Nobakht, MD

Dr. Nobakht practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Nobakht's NPI, 1811123151, was assigned on June 1, 2009. Dr. Nobakht holds California license A107561.

Dr. Nobakht's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Nobakht's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Nobakht is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Nobakht to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nobakht practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Nobakht's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Nobakht is board certified in nephrology by the American Board of Internal Medicine. Dr. Nobakht is licensed in California.

Dmand AI lists acute kidney failure, chronic hypertension, chronic kidney disease, fluid and electrolyte imbalances, heart failure, high cholesterol, kidney stone disease and parathyroid gland disorder among the conditions Dr. Nobakht treats.

CMS data shows 792 Medicare services from Dr. Nobakht across 7 procedure codes in 2024, for 259 Medicare patients. Medicare paid $72,661 for them.

CMS counts 259 Medicare patients who saw Dr. Nobakht in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 53% are also on Medicaid. Their average risk score is 5.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nobakht's median patient age at 61, with 46% women.

In 2024, Dr. Nobakht wrote 385 Medicare Part D claims for 55 patients. 74% of them were for generic drugs. CMS names the drug for 272 of them, across 14 drugs with 11 or more claims each, at $75,328 in total drug cost. In 2023, CMS named 129 claims across 7 drugs.

Dr. Nobakht accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nobakht as offering telehealth.

Dmand AI links 4 papers to Dr. Nobakht, published from 2011 to 2025. 2025 was the busiest year, with 2. Dr. Nobakht's most frequent co-authors are Ramy Magdy Hanna, MD, Mohammad Kamgar, MD and Rebecca S. Ahdoot, MD.

Dmand AI links Dr. Nobakht to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Glomerulonephritis, IGA and Glomerulonephritis.

CMS Open Payments shows 187 general payments to Dr. Nobakht from 20 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 39% of the total. Calliditas Therapeutics US Inc. paid the most, $34,863.

Dr. Nobakht is in network with 15 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.